Thelial Technologies
Dedicated to improving the treatment of diseases where biological barrier defects are a primary cause.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
N/A | Spinout | ||
| Total Funding | 000k | ||
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 1256 % | 36 % | (94 %) | (76 %) | 201 % | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (77 %) | (41 %) | (1200 %) | (10289 %) | (1487 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (94 %) | (67 %) | (1640 %) | (11487 %) | (1755 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Thelial Technologies S.A. is a pioneering company dedicated to reinforcing biological barriers in the human body. These barriers, such as the skin, mouth lining, and digestive tract lining, are crucial for maintaining good health. When these barriers fail, it can lead to increased health risks and a variety of diseases. Thelial Technologies aims to support and strengthen these barriers to promote overall health.
The company operates in the healthcare and biotechnology market, focusing on developing innovative solutions to enhance the body's natural defenses. Their primary clients include healthcare providers, pharmaceutical companies, and research institutions that are looking for advanced methods to improve patient health and prevent diseases.
Thelial Technologies employs a business-to-business (B2B) model. They generate revenue by licensing their patented platform technology and selling their products to other businesses in the healthcare sector. Their first product, benescoTM, was launched by Epinutra in the fourth quarter of 2020, marking a significant milestone in their journey.
The company is headquartered at the Incubadora Universidade de Lisboa in Lisbon, Portugal, where they continue to develop and refine their technology. Their research and development efforts have led to the discovery of several candidate compounds that have the potential to revolutionize the way we approach health maintenance and disease prevention.
In summary, Thelial Technologies S.A. is at the forefront of healthcare innovation, focusing on reinforcing the body's natural barriers to improve health outcomes. They serve a niche market with a B2B model, making money through product sales and technology licensing.
Keywords: healthcare, biotechnology, biological barriers, health maintenance, disease prevention, B2B, patented technology, benescoTM, innovation, Lisbon.